Physician profile
John Terry Fowler
NPI 1528075348
$5,113.96
in general payments reported to CMS, 2019-2025
57 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $799 · 2021: $1,102 · 2022: $731 · 2023: $1,011 · 2024: $400 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486.43 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $406.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $375.73 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $374.65 | 2019-2025 | |
| Novo Nordisk INC | $332.71 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $329.02 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $279.40 | 2023-2025 | Rexulti, Nuedexta |
| Ironwood Pharmaceuticals, INC | $244.22 | 2019-2023 | Linzess |
| Amarin Pharma, INC. | $189.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $177.71 | 2021-2023 | Verquvo |
| Amgen INC. | $174.26 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $122.04 | 2019 | |
| Insulet Corporation | $99.66 | 2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $98.36 | 2020-2021 | |
| Esperion Therapeutics, INC. | $94.69 | 2020-2023 | Nexletol |
Show all 54 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.